Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Interest in dextromethorphan (DM) has been renewed because of its anticonvulsant and neuroprotective properties. However, DM at supra-antitussive doses can produce psychotomimetic effects in humans. Recently, we demonstrated that DM exerts psychotropic effects in mice [Neurosci. Lett. 288 (2000) 76, Life Sci. 69 (2001) 615]. We synthesized a series of compounds with a modified morphinan ring system, with the intention of developing compounds that retain the anticonvulsant activity with weak psychotropic effects [Bioorg. Med. Chem. Lett. 11 (2001) 1651]. In order to extend our understanding of the pharmacological intervention of these morphinans, we assessed their behavioral effects, and then examined whether they exert protective effects on maximal electroshock
convulsions
(MES) in mice. Repeated treatment (20 or 40 mg/kg, i.p./day x 7) with DM or dextrorphan (a major metabolite of DM; DX) significantly enhanced locomotor activity in a dose-related manner. This locomotor stimulation was accentuated more in the animals treated with DX, and might be comparable to that of phencyclidine (
PCP
). By contrast, treatment with a metabolite of DM [3-methoxymorphinan (3MM) or 3-hydroxymorphinan (3HM)], 3-allyloxy-17-methylmorphinan (CPK-5), or 3-cyclopropylmethoxy-17-methylmorphinan (CPK-6) did not significantly alter locomotor activity or patterns. The behavioral effects mediated by these morphinans and
PCP
paralleled the effects of conditioned place preference. DM, DX, CPK-5, and CPK-6 had anticonvulsant effects against MES, while 3MM and 3HM did not show any anticonvulsant effects. We found that DM, DX, CPK-5 and CPK-6 were high-affinity ligands at sigma(1) receptors, while they all had low affinity at sigma(2) receptors. DX had relatively higher affinity for the
PCP
sites than DM. By contrast, CPK-5 and CPK-6 had very low affinities for
PCP
sites, suggesting that
PCP
sites are not requisites for their anticonvulsant actions. Our results suggest that the new morphinan analogs are promising anticonvulsants that are devoid of
PCP
-like behavioral side effects, and their anticonvulsant actions may be, in part, mediated via sigma(1) receptors.
...
PMID:New morphinan derivatives with negligible psychotropic effects attenuate convulsions induced by maximal electroshock in mice. 1258 25
Phencyclidine (
PCP
) produces schizophrenia-like psychosis and acute
PCP
-intoxications; however, whether glutamate/NMDA-receptor blockade by
PCP
modulates or not these mechanisms has remained to be clarified. To clarify this mechanism, we determined interaction among voltage-gated Na(+)-channel inhibitor, tetrodotoxin (TTX), Golgi-disturbing-agent, brefeldin-A (BFA), and
PCP
on releases of glutamate, GABA, and monoamine in prefrontal-cortex (pFC), using microdialysis.
PCP
increased basal monoamine release, whereas it decreased basal GABA release, without affecting glutamate release.
PCP
increased K(+)-evoked monoamine release, whereas it decreased K(+)-evoked glutamate and GABA releases. TTX reduced basal monoamine and GABA releases without affecting glutamate release, whereas BFA did not affect them. Interestingly, BFA and TTX inhibited
PCP
-associated basal monoamine release and abolished
PCP
-induced reduction of basal GABA release without affecting glutamate release. BFA and TTX reduced K(+)-evoked releases of all neurotransmitters. BFA inhibited
PCP
-associated K(+)-evoked monoamine release, but TTX did not affect them.
PCP
-induced reduction of K(+)-evoked GABA and glutamate releases was abolished by TTX and BFA. These results indicate that
PCP
reduces GABAergic transmission via NMDA-receptor blockade and activates intracellular endoplasmic-reticulum-associated signal-transduction, resulting in enhancement of monoaminergic transmission in pFC. Thus, these
PCP
properties support the hypothesis that mechanisms of the neurological symptoms of acute
PCP
-intoxication,
convulsion
, and rhabdomyolysis may be involved in both reduction of GABAergic-transmission and activation of endoplasmic-reticulum-associated signal-transduction induced by
PCP
.
...
PMID:Hyperactivity of endoplasmic reticulum associated exocytosis mechanism contributes to acute phencyclidine intoxication. 1521 46
We showed that dextromethorphan (DM) provides neuroprotective/anticonvulsant effects and that DM and its major metabolite, dextrorphan, have a high-affinity for sigma(1) receptors, but a low affinity for sigma(2) receptors. In addition, we found that DM has a higher affinity than DX for sigma(1) sites, whereas DX has a higher affinity than DM for
PCP
sites. We extend our earlier findings by showing that DM attenuated trimethyltin (TMT)-induced neurotoxicity (
convulsions
, hippocampal degeneration and spatial memory impairment) in rats. This attenuation was reversed by the sigma(1) receptor antagonist BD 1047, but not by the sigma(2) receptor antagonist ifenprodil. DM attenuates TMT-induced reduction in the sigma(1) receptor-like immunoreactivity of the rat hippocampus, this attenuation was blocked by the treatment with BD 1047, but not by ifenprodil. These results suggest that DM prevents TMT-induced neurotoxicity, at least in part, via sigma(1) receptor stimulation.
...
PMID:Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats. 1738 60
Reasoning and problem solving deficits have been reported in schizophrenic patients. In the present study, we have tested rats in a two-lever reversal learning task in a Skinner box to model these deficits. In other studies using the Skinner box, atypical antipsychotics fully reversed phencyclidine (
PCP
)-induced impairments in reversal learning which is in contrast to clinical observations where antipsychotics lack the ability to fully reverse cognitive deficits in schizophrenia. Therefore, it can be argued that the outcome of these tests may lack predictive value. In the present study, after training on a spatial discrimination between two levers, rats were exposed to a reversal of the previously learned stimulus-response contingency during 5 days. We first investigated the effects of sub-chronic treatment with the non-competitive N-methyl-d-aspartate (NMDA) antagonists dizocilpine (MK-801) and
PCP
on reversal learning and extinction in male Sprague Dawley rats. Subsequently, we studied the effects of different
PCP
treatment regimes. Then, we investigated whether the atypical antipsychotics risperidone and clozapine and the 5-hydroxytryptamine6 (5-HT6) antagonist GSK-742457 could reverse the
PCP
-induced deficits. All drugs were administered subcutaneously (s.c.). MK-801 did not impair reversal learning, while
PCP
(1.0 and 2.0 mg/kg) induced a clear deficit in reversal learning. Both compounds, however, disrupted extinction at all tested doses. Risperidone and clozapine were both ineffective in significantly ameliorating the
PCP
-induced deficit in reversal learning which
fits
well with the clinical observations. The lowest dose of clozapine (1.25 mg/kg) had an intermediate effect in ameliorating the deficit in reversal learning induced by
PCP
(not different from control or
PCP
-treated rats). The lowest dose of GSK-742457 (0.63 mg/kg) fully reversed the
PCP
-induced deficits while the higher dose (5.0 mg/kg) had an intermediate effect.
...
PMID:Effects of risperidone, clozapine and the 5-HT6 antagonist GSK-742457 on PCP-induced deficits in reversal learning in the two-lever operant task in male Sprague Dawley rats. 2338 14
Ketamine is a rapid-acting anesthetic commonly used during surgical procedures in both animals and humans, as an experimental drug in the treatment of chronic pain, and as a probe for the study of the cause of schizophrenia. When used medically as an anesthetic it is administered as an intravenous (IV) solution, but when diverted to the illicit market it can be injected, snorted, smoked, or consumed in drinks. Ketamine produces effects similar in some respects to phencyclidine (
PCP
) and lysergic acid (LSD), but of shorter duration. Psychedelic effects are produced quickly by low doses of the drug, although larger doses are frequently used in an attempt to produce "near-death" experiences.
Convulsions
and death can be caused by higher doses, although most deaths in which ketamine is detected are the result of poly-drug use or trauma. Reports of ketamine use at rave parties attended by young adults appear to be on the rise. The effects from ketamine last from 1-5 hours, and ketamine can be detected in the urine for a period of 1-2 days following use.
...
PMID:Katamine - Effects on Human Performance and Behavior. 2625 89
<< Previous
1
2
3